Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
156 hedge funds and large institutions have $1.84B invested in Akero Therapeutics in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 56 reducing their positions, and 22 closing their positions.
49% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $16.9M
2% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 56
1.69% less ownership
Funds ownership: 104.03% → 102.34% (-1.7%)
4% less funds holding
Funds holding: 162 → 156 (-6)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
30% less capital invested
Capital invested by funds: $2.65B → $1.84B (-$806M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$50M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$21M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$61.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$52.6M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$33.1M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$26.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$18.8M |
AKRO Hedge Fund Activity: Q1 2023 in Review
156 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2023, worth a combined $1.84B — down 30% from $2.65B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AKRO and 19 opened new positions — a net loss of 3 holders — while 56 trimmed existing stakes and 57 added.
The largest buyer was Fidelity Investments, adding an estimated $50M. The largest seller was Avidity Partners Management, cutting an estimated $61.4M.
- 156 institutional investors held Akero Therapeutics (AKRO) as of Q1 2023, down from 162 in Q4 2022.
- Funds reported $1.84B of Akero Therapeutics stock for Q1 2023, down 30% quarter-over-quarter.
- 19 funds opened new Akero Therapeutics positions in Q1 2023 and 22 closed out, a net change of -3 holders.
- The largest Akero Therapeutics buyer in Q1 2023 was Fidelity Investments, an estimated $50M added.
- The largest Akero Therapeutics seller in Q1 2023 was Avidity Partners Management, an estimated $61.4M sold.
Based on aggregated 13F filings for Q1 2023.